Oculis Holding AG Logo

Oculis Holding AG

Clinical-stage biopharma developing therapies for ophthalmic and neuro-ophthalmic diseases.

OCS | IC

Overview

Corporate Details

ISIN(s):
CH1242303498 (+1 more)
LEI:
5067005370C2KK324336
Country:
Switzerland
Address:
Bahnhofstrasse 7, 6300 Zug

Description

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-05 10:00
Oculis Publishes Results of 2025 Annual General Meeting
English 6.4 KB
2025-06-03 23:00
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 949 bytes
2025-06-03 10:00
Oculis to Participate in Upcoming June Investor Conferences
English 4.3 KB
2025-05-09 22:05
Oculis birtir boð á aðalfund
Icelandic 4.6 KB
2025-05-09 22:05
Oculis Publishes Invitation to the Annual General Meeting
English 4.2 KB
2025-05-09 21:05
Oculis Publishes Invitation to the ..
Icelandic 4.6 KB
2025-05-09 21:05
Oculis Publishes Invitation to the ..
English 4.2 KB
2025-05-08 22:05
Oculis birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir áfanga í rekstri …
Icelandic 22.3 KB
2025-05-08 22:05
Oculis Reports Q1 Financial Results and Provides Company Update
English 19.6 KB
2025-05-08 21:05
Oculis Reports Q1 Financial Results..
Icelandic 22.1 KB
2025-05-08 21:05
Oculis Reports Q1 Financial Results..
English 19.4 KB
2025-05-07 09:00
Oculis to Present at Upcoming May I..
English 4.9 KB
2025-05-01 09:00
Oculis to Present its Innovative La..
English 19.0 KB
2025-04-25 21:00
Oculis Updates Share Capital
English 2.3 KB
2025-04-15 09:00
Oculis Hosts R&D Event Today to Sho..
English 8.5 KB

Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oculis Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oculis Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.